Hand, Foot and Mouth Disease Global Clinical Trials Review, H2, 2017

2017-08-31
Price :
Published : Aug-2017
No. of Pages : 47

Hand, Foot and Mouth Disease Global Clinical Trials Review, H2, 2017

Summary

GlobalData’s clinical trial report, “Hand, Foot and Mouth Disease Global Clinical Trials Review, H2, 2017” provides an overview of Hand, Foot and Mouth Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Hand, Foot and Mouth Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

OraSure Technologies Inc (OSUR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; and antigens for influenza type A and type B. OraSure also sells immunoassay tests and reagents for insurance risk assessment, substance-abuse testing and forensic toxicology applications; and products for the cryosurgical removal of warts and several other benign skin lesions. The company distributes its products to various hospitals, clinics, community-based organizations and other public health organizations, distributors, clinical laboratories, and commercial and industrial entities. The company s......
$250

Rite Aid Corp (RAD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Rite Aid Corp (Rite Aid) is retail drugstore chain. The company sells prescription drugs and a wide range of other merchandise such as, over-the-counter (OTC) medications, personal care items, health and beauty aids, cosmetics, household items, beverages, convenience foods, greeting cards, seasonal merchanise, photo processing and others. Rite Aid services portfolio include pharmacy-related solutions including fully integrated mail, specialty and compounding pharmacy services. The company also has a technology which helps its customer to fill or refill their prescription through internet under website www.riteaid.com. It operates through subsidiaries and retail drugstores in the US. Rite Aid is headquartered in Camp Hill, Pennsylvania, the US. Rite Aid Corp (RAD) - Pharmaceutical......
$250

Biotest AG (BIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Biotest AG (Biotest) is a provider of pharmaceutical and biotherapeutic drugs which develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products comprise clotting factors, immunoglobulins, albumin and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East and Africa. It has subsidiaries and sales companies in Austria, Switzerland, France, Great Britain, Italy, Hungary, Spain and in Brazil. Biotest is headquartered in Dreieich, Hessen, Germany. Biotest AG......
$250

Emisphere Technologies Inc (EMIS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Emisphere Technologies Inc (Emisphere) is a specialty pharmaceutical and drug delivery company. The company in partnership with global pharmaceutical companies develops novel oral formulations of existing injectable bio-pharmaceutical products, besides new chemical entities, using its Eligen technology. Its lead product Eligen B12, is the first and only once-daily oral prescription medical food approved in the US for treatment of vitamin b12 deficiency. The product is sold through a range of distributors, sellers, and other sources. Emisphere also uses its proprietary Eligen technology to produce novel oral formulations of therapeutic agents. The company's product pipeline includes prescription drugs and medical food products that are being developed in partnership or internally. ......
$250

Heron Therapeutics Inc (HRTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Heron Therapeutics Inc (Heron), formerly A.P. Pharma, Inc., is a biotechnology company that uses its proprietary polymer-based drug delivery platform to develop novel, patient-focused therapeutic products for patients suffering from cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, which improves the therapeutic profile of injectable pharmaceuticals. The company's first commercial product Sustol is an extended-release injection indicated in combination with other antiemetics in adults for the prevention of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Heron's developmental pipeline includes HTX-011 for post-operative pain management and Cinvanti (HTX-019) for ......
$250

Vericel Corp (VCEL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Vericel Corp (Vericel) formerly Aastrom Biosciences, Inc. is a medical device company that develops patient-specific expanded cellular therapies to repair and regenerate damaged tissue for the treatment of severe, chronic ischemic cardiovascular diseases. It markets two autologous cell therapy products in the US: Carticel, an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement for the treatment of patients with deep-dermal. The company also develops MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treating advanced heart failure. It has manufacturing facilities in Cambridge, Massachuset......
$250

BELLUS Health Inc (BLU) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company's pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second indication called sarcoidosis; AMO-01 related to Fragile X syndrome and ALZ-801 for the treatment of Alzheimer's disease. BELLUS Health is headquartered in Laval, Quebec, Canada. BELLUS Health Inc (BLU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity......
$250

Charles River Laboratories International Inc (CRL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. The organization also offers clinical support, manufacturing support and operations and staffing support. It focuses on providing solutions targeted against therapeutic areas of cardiovascular, central nervous system, metabolic inflammation, oncology, ophthalmology, respiratory disease and musculoskeletal disease. Charles River caters its products and services to global pharmaceutical companies, biotechnology companies, government agencies, as well as leading hospitals and academic institutions, ......
$250

Incyte Corp (INCY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company's lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. JAKAFI is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd. (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company's pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lu......
$250

Cytokinetics Inc (CYTK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases, which compromise muscle performance. The company's lead drug candidate, tirasemtiv, a fast skeletal muscle troponin activator, is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis (ALS). Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase III clinical trials for heart failure. Its other pipeline products include CK-2127107 for the treatment spinal muscular atrophy and chronic obstructive pulmonary disease. It has licensing agreements with Amgen and Astellas for the development of its drug candidates. Cytokinetics is headquartered in S......
$250